A key element of PTC's strategy is to establish strategic collaborations. These collaborations provide expanded
opportunities to apply PTC's scientific approach to additional therapeutic areas, access to development and
commercialization capabilities, and significant financial resources.
|
CV Therapeutics — Exclusive research collaboration and licensing arrangement for the development of orally bioavailable small molecules through the application of PTC's proprietary GEMS (Gene Expression Modulation by Small-Molecules) technology.
|
|
Cystic Fibrosis Foundation — $1.7 million grant to support the development of PTC124 for the treatment of cystic fibrosis (CF) due to a nonsense mutation..
|
|
Muscular Dystrophy Association (MDA) — $1.5 million grant to support the development of PTC124 for the treatment of Duchenne muscular dystrophy (DMD) due to a nonsense mutation..
|
|
Parent Project Muscular Dystrophy (PPMD) — Support for preclinical development of PTC124 for the treatment of Duchenne muscular dystrophy (DMD) due to a nonsense mutation. Collaboration to discover new drugs to treat Duchenne muscular dystrophy (DMD): Project Catalyst.
|
|
Pfizer Inc. - An exclusive research collaboration and licensing agreement for the development of pharmaceuticals through the application of PTC’s GEMS (Gene Expression Modulation by Small-molecules) technology.
|
|
Schering-Plough Corporation — $200 million collaboration for the development and commercialization of the compounds in the hepatitis C program.
|
|
Spinal Muscular Atrophy Foundation — $1.6 million grant to support discovery of new treatments for spinal muscular atrophy (SMA).
|